Xintela

Xintela AB is a biomedical company leveraging its unique integrin platform to address high unmet needs in cartilage damage and aggressive cancers. Founded in 2013 and based in Lund, Sweden, its strategy centers on developing a dual pipeline: XSTEM, an α10β1-selected mesenchymal stem cell therapy for osteoarthritis, and targeted oncology programs against the αvβ3 integrin. As a publicly traded entity on Nasdaq First North, Xintela is progressing its lead candidate through clinical validation while exploring strategic partnerships to accelerate development.

Proprietary platform for selecting cells based on specific integrin expression (α10β1 for cartilage-progenitor stem cells, αvβ3 for cancer cell targeting), enabling development of potent regenerative therapies and targeted oncology drugs.

In regenerative medicine, Xintela competes with other MSC and cell therapy developers, differentiating via its α10β1-selected cells. In oncology, it faces other ADC developers and novel immuno-oncology approaches, aiming to stand out with its αvβ3-targeting mechanism for glioblastoma.